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TransplantationOsteonecrosis is a serious condition involving bone destruction that frequently requires surgical treatment to
rebuild the joint.While there is an abundanceof literaturedocumenting corticosteroid related osteonecrosis, there
is no consensus as to the relative risk of osteonecrosis after administration of steroids via parenteral, oral, topical,
inhaled and other routes. This risk is an important prognostic indicator because identification and conservative
intervention can potentially reducemorbidity associatedwith aggressive surgical treatment of osteonecrosis. This
paper provides insight into establishing guidelines related to the risk of developing osteonecrosis as a result of
corticosteroid use. Case studies, retrospective studies and prospective studies in humans on different
corticosteroids and varied dosages were assessed. Most cases of osteonecrosis are secondary to systemically
administered corticosteroids and/or high dose daily therapy, particularly in patients with underlying
comorbidities including connective tissue diseases, hyperlipidemia, or previous trauma. Previous case reports of
osteonecrosis related to inhaled or topical use of steroids are complicated by the fact that in the great majority of
cases, the patients are also treatedwith systemic steroids prior to the development of osteonecrosis. Based on the
literature, a set of recommendations regarding the risk of osteonecrosis in patients on steroids was formulated.acific Coast Allergy, 1585 Railroad Avenue, Crescent City
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Take-home messages .1. Introduction
Osteonecrosis, otherwise known as ischemic necrosis, avascular
necrosis, aseptic necrosis of bone, osteochondritis dissecans or bone
death results in collapse of the normal architecture of the skeletal
framework, leading to significant clinical morbidity, including
progressive joint pain and loss of function [1]. The most common
cause of osteonecrosis is trauma, which leads to mechanical
interruption of nutrient delivery to the bone, but there are many
non-traumatic causes or associations as well. By far the most well
known association is related to the use of corticosteroids, but other
iatrogenic causes including alcoholism, radiation treatment, bispho-
sphonate use, and possibly even cigarette smoking, exist. Other
etiologies for osteonecrosis include anatomical deformities such as
Legg–Perthes–Calves disease, dislocation of a joint and slipped
femoral capital epiphyses. Osteonecrosis has also been reported to
occur as a result of exposure to hyperbaric conditions, and has been
tenuously associated with conditions in which a lipid disorder exists,
such as lipid storage diseases and even pregnancy. The list of potential
causes is lengthy and beyond the scope of this article, the focus of
which is to attempt to navigate the extensive literature on
corticosteroid associated osteonecrosis in order to decipher trends
in risk related to corticosteroid use.2. Corticosteroids and osteonecrosis
Harvey Cushing first recognized the adverse effects of hypercorti-
solism on bone tissue in the early 1930s. Since then, multiple reports
of bone death have increased our awareness of the potential for the
development of osteonecrosis in patients on corticosteroids [1,2].
Steroid induced osteonecrosis has in fact been described in numerous
publications, ranging from case reports to prospective studies. There is
no doubt that there is a real risk of osteonecrosis with steroid use.
However, it is often difficult to determine the extent of causality
between steroid use and osteonecrosis because many of the
conditions they are used to treat can also cause or predispose to
osteonecrosis. Indeed, there appears to be a significant difference in
the incidence of corticosteroid induced osteonecrosis depending on
the underlying condition for which corticosteroids are administered.
It is also not clear whether the risk of osteonecrosis is more closely
related to cumulative dose, maximum dose or duration of therapy.
Topical, inhaled and oral glucocorticoids are some of the most
frequently used treatments for eczema, asthma, allergic rhinitis,
pulmonary diseases, autoimmune disease and other inflammatory
diseases, and it is therefore vital to identify those at particular risk for
complications.
The association between corticosteroid use and osteonecrosis was
first described in renal transplant patients who were undergoing
immunoablation or immunosuppression as part of their transplant
regiment [3]. Multiple reports elucidating this connection have been
published and a cause–effect relationship is now well established.
Early diagnosis has proven to be problematic as the majority of
patients are asymptomatic until significant damage to bone has
occurred. Osteonecrosis tends to occur in a younger, more active age
group and because there are limited treatment options for advanced
disease, early identification is vital. Multiple treatment options have
been explored for osteonecrosis. Presently, the best option for
preventing complete joint replacement is the diagnosis of subjects
in earlier stages before the joint becomes compromised. Again, thisemphasizes the importance of identifying high-risk patients as early
as possible.
3. Epidemiology
The incidence of steroid induced osteonecrosis is estimated to be
approximately 10,000 to 20,000 per year in the United States. Steroid
induced osteonecrosis accounts for 10% or more of the 500,000 total
joint replacements performed annually in the United States [4].
Approximately 75% of patients with steroid induced osteonecrosis are
in their 30's to 60's, with the exception of SLE patients who make up a
younger cohort [5]. The average age of steroid induced osteonecrosis
is 33 and since the only treatment is surgery, these individuals will
require multiple surgeries over their lifetime [6]. Male to female ratio
is 7:3 with the exception of patients with underlying systemic lupus
erythematosus (SLE), in which there is a higher female proportion.
Early diagnosis is essential as prognosis and treatment options decline
as the disease progresses.
Corticosteroid use now falls behind only trauma as the most
common etiology of osteonecrosis, with a prevalence ranging
between 3 and 38% [1]. It is estimated that 30 million Americans
require glucocorticoids for various conditions. The incidence of steroid
induced osteonecrosis may reach 40%, depending on the duration,
dose or underlying disease [6,7].
4. The clinical presentation of steroid induced osteonecrosis
The most commonly affected sites of osteonecrosis include the
femoral and humeral heads, but osteonecrosis can occur elsewhere as
well, including knees (femoral condyles and proximal tibia) [8], small
bones of the foot, ankle, and hands (including scaphoid and lunate),
vertebrae and bony structures of the face [9]. The onset of steroid
induced osteonecrosis is usually insidious or vague in early stages.
Symptoms may not occur for weeks to up to a year after cessation of
steroid use. The pain may be referred. For example, in osteonecrosis
of the femoral head, unilateral hip pain is usually the presenting
symptom, but pain may also be referred to the groin, thigh, knees or
buttocks. The contralateral hip will become affected within 2 years
in up to 55% of cases [1]. Function may be affected as well, and many
patients will present with a painful limp, which is aggravated by
weight bearing and partially relieved by rest. Progression of pain is
common and in advanced disease, pain is also present at rest. Range
of motion and disability are progressive in the late stages, and as hip
arthroplasty becomes imminent, pharmacologic intervention is of
suboptimal effectiveness and is limited to analgesics. Several
classification systems have been proposed to grade the severity of
osteonecrosis. In the Ficat and Arlet scheme, stages 1–2 are
reversible while stages 3–4 denote end stage disease with irrevers-
ible damage.
5. Methods
Medline search of published studies with key words “osteonecro-
sis” and “corticosteroids” from 1961 to 2010 was conducted. From
this search and their accompanying references a total of 490 studies
dated from 1959 to the present were reviewed, and 396 were
determined to be pertinent to our discussion. Studies consisted of
animal and human studies. The “human” literature included case
reports, reviews, prospective studies and retrospective studies.
Table 1
Relative potencies of corticosteroids.
Preparation Dose (mg) RP Duration
723C. Powell et al. / Autoimmunity Reviews 9 (2010) 721–743Manuscripts were reviewed with particular reference to the patho-
genesis, clinical presentations, risk factors, and steroid dose associa-
tion with osteonecrosis.Hydrocortisone 10 1 Short
Cortisone 12.5 0.8 Short
Prednisone 2.5 4 Intermediate
Prednisolone 2.5 4 Intermediate
Methylprednisolone 2 5 Intermediate
Triamcinolone 2 5 Intermediate
Paramethasone 1 10 Long
Dexamethasone 0.4 25 Long
Betamethasone 0.3 33 Long
The relative potency relates only to drug half-life, not biologic half-life. In other words,
the effect of corticosteroids may persist long after the drug has dissipated from the sera
or tissues.6. Results
It has been reported that those at particular risk of development of
osteonecrosis have received high dose, long term and long acting
preparations of steroid. Similarly, cumulative dosing has also been
reported as having a significant risk in pathogenesis. However,
multiple studies have also reflected occurrence in those treated
with short courses of high dose steroid, and more rarely, with low
dose, short duration courses including inhaled and topical prepara-
tions. Animal models have helped to establish a cause and effect
relationship to steroid dosing.Table 2
Risk factors for the development of osteonecrosis.
Medications
Corticosteroids
Protease inhibitors
Connective tissue diseases
APLS
Ehlers danlos
AS
GCA
PM/DM
PMR
RA
SCL
Sjogrens
SLE
Hematologic diseases
ALL
Aplastic anemia
Lymphoma
PML
Post-BMT
Solid malignancies
Bronchogenic CA
Ovarian CA
Testicular carcinoma
Organ transplant
Heart
Lung
Renal
Hemoglobinopathies
DIC
Hemophilia
Polycythemia
Sickle cell
Thallasemia6.1. Animal studies
The pathogenesis and immunology of osteonecrosis will be
discussed in subsequent articles in this series on osteonecrosis. In
2008, Motomura et al. [10] described the relationship between
steroid dosing and osteonecrosis in rabbit models. Rabbits were
treated with 1, 5, 20, and 40 mg/kg of methylprednisolone (MPSL),
resulting in incidence of osteonecrosis of 0, 42%, 70%, and 96%,
respectively. Histologically, reparative tissues around the osteone-
crosis sites were observed in the rabbits with 5 mg/kg MPSL, but not
observed in rabbits with 20 and 40 mg/kg MPSL. On hematological
examination, hyperlipidemia and thrombocytopenia were most
apparent in the rabbits receiving 40 mg/kg MPSL. Overall, this
study highlights the statistically significant association of dose and
osteonecrosis occurrence, and suggests that hyperlipidemia is
important in its pathophysiology. Similarly, Yamamoto et al. [11],
examined the effect of pulsed doses of methylprednisolone acetate
on bone and bone marrow tissue in rabbits, and observed the
formation of osteonecrosis at 4, 6, 8, and 10 weeks. Forty-three
percent of the rabbits developed osteonecrosis in multiple sites by
the fourth week after injection with 20 mg/kg of methylpredniso-
lone. Other factors related to altered lipid metabolism also were
found to be present, including fatty liver, hyperlipidemia, and
intraosseous fat embolism. In 2009, Yang et al. [137], studied
mouse models of steroid induced osteonecrosis. Interestingly, the
authors found discontinuous therapy was less osteonecrotic than
continuous dexamethasone treatment, consistent with the possible
benefits of a “steroid holiday” seen in clinical settings.Genetic
Gaucher disease
Legg–Calve–Perthes disease
GI
Crohn's/UC
Pancreatitis
Refractory celiac disease
Metabolic/endocrine
Cushing's
Hyperlipidemia
Hyperparathyroidism
ID
HIV
Meningococcemia
Misc
Alcohol
Dybaric
Fat emboli
Idiopathic
Pregnancy
Premature ovarian failure
Radiation exposure
Smoking
Spinal cord injury6.2. Human studies
The case reports of corticosteroid induced osteonecrosis are
presented first, followed by groupings of larger prospective, retro-
spective, case series, or cohort studies, which have been divided by
underlying disorder. The underlying diseases with a high reported
prevalence of steroid induced osteonecrosis include systemic lupus
erythematosus, renal transplant, bone marrow transplant, cardiac
transplant, lung transplant, liver transplant, acute lymphocytic
leukemia, Hodgkin's disease, multiple myeloma undergoing chemo-
therapy, severe acute respiratory syndrome (SARS), multiple sclerosis,
and neurosurgical patients. The majority of studies of corticosteroid
induced osteonecrosis have been reported in SLE patients or renal
transplant patients. In most of these and other studies, the steroid
administered differs in name and in properties, such as half-life or
relative strength. In order to facilitate comparison, a table outlining
the difference between commonly used corticosteroids is shown in
Table 1.
Table 3
Case reports of steroid induced osteonecrosis with particular attention to steroid dosing. Organized chronologically.
Study/Ref. No.
of pts
Site Steroid route Daily dose Duration Cumulative dose prednisone
equivalent
Other risk factors
Kontovazenitis
et al. [78]
1 Knee IA Intraarticular steroid not reported NA NA NA
Yildiz et al. [79] 1 Knee/femoral head IV/PO MPSL/prednisone 1000 mg×3 days,
500 mg×3 days, and 250 mg×3 days,
followed by taper over 3 weeks
4 weeks 6562 mg during pulse. ITP
Total in taper not described.
Kosaka et al. [80] 1 Bilateral femoral heads IV/PO prednisolone Pulse; taper 423 days 7365 mg Breast Ca; radiation
Gunal et al. [12] 1 Bilateral femoral heads IM prednisolone Single IM injection Single IM injection 75.5 mg None
Hussain et al. [81] 3 Bilateral femoral head;
bilateral knees;
bilateral knees
PO MPSL equivalent. Varied dose. 11 days 981 mg; 1500 mg; 1680 mg None
Drigo et al. [17] 1 Femoral head Topical/po/inhaled 3-day treatment with topical steroids
(mometasone lotion 0.1%); 10-day course
of oral steroid (betamethasone 1 mg/kg for
three days with tapering of the dose in the
next seven days) and 3 courses of inhaled
beclometasone dipropionate (800 μg/day)
lasting 2–3 weeks
Topical—3 days;
oral—10 days;
inhaled—3 courses
lasting 2–3 weeks each
NA None
Yamamoto [13] 1 Femoral head IA MPSL 80 mg×1 Single IA injection 100 mg None
Tasic et al. [82] 1 Bilateral talus IV/PO MPSL/prednisone 40 mg po×4 weeks; pulse IV
500 mg×3; prednisone 40 mg/day for 10 days
followed by 25 mg on alternate days and then
tapered; additional prednisone required
~1 year 4730mg prednisone and 1500
mgMPSL
(1875mg pred equiv).
Nephrotic syndrome
Lanyi et al. [83] 1 Left “foot”; tibia PO Prednisone 40 mg/day with additional ?
steroid at onset
12 weeks N3360 mg Crohn's
Jafri et al. [16] 1 Knee Inhaled/intraarticular 40 mg Depo-Medrone×1; long term inhaled
steroids
NA NA ?Ethanol abuse
Ito et al. [84]
(Japanese study)
1 Knee PO Prednisolone 10 years NA Ulcerative colitis
Loddenkemper
[85]
1 Femoral head IV/PO Prednisolone (maximum dose 500 mg/day
(pulse therapy; average dose 15 mg/day)
~20 years ~106,800 mg prednisolone MCTD
Skinner [86] 2 Femoral head PO Prednisolone 40 mg×10 days 10 days×4 courses;
6 weeks
NA Infertility
Prednisolone 40 mg/day×6 weeks Tobacco
Clinkscales [87] 1 Knee/ankle IV methylprednisolone
7 months prior.
NA 7 days 4.5 g MPSL (5625 mg pred
equivalent)
None
Sakai et al. [88] 1 Femoral head NA NA NA NA NA
Reichert-Pénétrata
et al. [89]
1 Bilateral femoral head Topical Betamethasone dipropionate Daily average
30 mg×5 years; intermittent use×20 years
~20 years 445,000 mg None
Nasser et al. [90] 1 Bilateral femoral head IM 16 total injections of depot corticosteroid: nine
of Kenalog (triamcinolone; Bristol-Myers Squibb,
Hounslow) 40 mg and seven of Depo-Medrone
(MPSL) 80 mg.
Over 10 years 360mg triamcinolone (450mg pred);
560mgmethylprednisolone
(700mg pred)
None
Kubo et al. [91] 1 Femoral head Topical 2–3 g/day of 0.05% clobetasol propionate 2 years and 10 months ~2530 g over time period None
Abhyankyan
et al. [92]
1 Femoral head IV Dexamethasone 8 mg q 8 hourly 5 days 800 mg Acute promyelocytic
leukemia
Spencer et al. [93] 1 Femoral head IM Betamethasone two doses of 12 mg over 24h×6 Over 3 months 1166 mg Pregnancy
Carter et al. [94] 2 Femoral head PO Prednisone 40–80 mg po q day; prednisone 60 mg
po q day with taper over 3 months
3–4 months NA Crohn's
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Table 3 (continued)
Study/Ref. No.
of pts
Site Steroid route Daily dose Duration Cumulative dose prednisone
equivalent
Other risk factors
Braverman et al.
[95]
1 Bilateral knees Enemas Hydrocortisone 100 mg retention enemas×6 3 months 150 mg Ulcerative colitis
Hurel [96] 1 Femoral head IV/PO Dexamethasone 8mg/day×2months; dexamethasone
1mg/day×?; prednisolone 5 mg po q day×?
~2 months 3200 mg None
Gogas et al. [97] 1 Femoral head IV Dexamethasone 20 mg IV×6; dexamethasone 20
mg IV×12
18 total doses over 3 years 4.32 g Ovarian Ca;
chemotherapy
Hui et al. [98] 4 NA IV Dexamethasone NA Total dexamethasone dose
equivalent to that of prednisone,
3.4–5.0 g/M2
Acute lymphocytic
leukemia
Cowan [99] 1 Mandible PO/IV Prednisone 60 mg po q day with taper;
intermittent pulse therapy
~2 years NA Myasthenia gravis
Jones et al. [100] 1 Multifocal knees/hips,
ankle
IV Dexamethasone 10 mg IV q 6 h 10 days Dexamethasone 200–250 mg
(1333–1666 mg pred)
Bronchogenic Ca
Madsen et al. [101] 1 Femoral head PO Prednisolone 40 mg po BID 28 days 2–3 g Ulcerative colitis
Osebold [102] 1 Humeral head IV Dexamethasone pulse and taper 26 days 5375 mg Cord injury
Mizuta [103] 1 Bilateral patella PO Prednisolone 25 mg/day 5 years 44,500 mg Polymyositis
Beyer et al. [104] 1 Bilateral femoral head,
capitellum, trochlea
PO Prednisone 120 mg/day ~5 years NA Dermatomyositis
Obrien et al. [15] 1 Femoral head Inhaled/IM Inhaled steroids;16 injections of depot cs: 9 of
Kenalog 40 mg and 7 of Depo-Medrone 80mg.
Over ten years NA Allergic rhinitis
McCarty et al. [105] 1 Knee PO/IA IA injections; 2× MPSL tablets×6 days ~12 days NA None
Adleberg et al.
[8,106]
1 Talus PO/IA Prednisone 5 mg/day; IA “cortisone×3” NA NA None
Kelman et al. [8] 2 Knee PO NA NA NA NA
Eghwrudjakpor
et al. [107]
1 Femoral head PO Hydrocortisone 60 mg/day with taper ~3 months NA None
Archer et al. [108] 1 Knee/femoral head PO/IV Dexamethasone. The highest daily dose was 32 mg
in four divided doses for a one day period. This was
tapered over the remaining two weeks.
15 days 248 mg of dexamethasone
over a fifteen day period
(1653 mg pred)
None
Gold et al. [109] 1 Bilateral knee PO Prednisone 60 mg po×2 months 2 months 3600 mg IVDA. Did not consent
for HIV testing. Steroid
treatment for ITP.
Jones et al. [110] 3 Femoral head IV High dose pulsed MPSL: single dose of 1 g vs.
500 mg vs. 40 mg (double blind study)
Single dose 1250 mg vs. 625 mg vs. 50 mg RA
Preston-thomas
et al. [111]
2 Bilateral femoral head;
left knee and left
femoral head
IV/PO Patient 1: betamethasonone 16 mg/day×22 days
and then on a “reducing dose”×11 days; patient
2: 1st episode: betamethasone 24 mg×1, followed
by 16 mg/day×19 days. 2nd episode: betametasone “
again given for 19 days.”
33 days; 39 days 352mg+unknown taper dose;
632mg (assuming 16mg/day was
administered during 2nd episode
(2933mg; 5266mg of pred equiv)
Cerebral edema
treatment
Yamaguchi [112] 2 Patella PO Prednisone? NA NA Asthma;SLE
Kalliel et al. [14] 1 Left femoral head PO/inhaled Prednisone 40mg/day with taper×2; inhaled steroids N1 year NA Asthma
Tang et al. [113] 1 NA Topical 0.025% Flucinolone topical cream (1 tube—5 g every
2 days)
4 years 3560 g (equivalent to prednisolone
1140mg)
Psoriasis
Spencer et al. [114] 1 Femoral head PO Prednisolone 100mg BID×(time period not reported);
IV “high dose”MPSL (quantity not reported);
prednisolone 4mg maintenance for 10 years
10–15 years NA Renal transplant
Hogan et al. [115] 1 Bilateral hip Topical Long term use of 0.05% Clobetasol propionate
ointment, ave 250 g/month
5 years 15,000 g of clobetasol Ethanol abuse
Aoki [116] 2 Hip Oral Average dose of 150 mg per day; average
dose of 53 mg per day
18 days Prednisolone equivalent 2675
mg and 1050 mg, respectively
None
Roseff et al. [117] 1 Femoral head IM/IA Multiple soft tissue and intraarticular injections N18 years Estimate of 13 g of MPSL
(16,250 mg pred)
None
(continued on next page)
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Table 3 (continued)
Study/Ref. No.
of pts
Site Steroid route Daily dose Duration Cumulative dose prednisone
equivalent
Other risk factors
Fast et al. [118] 1 Femoral and humeral heads NA Short term treatment for brain edema NA NA NA
Taylor et al. [119] 3 Femoral head IV/PO Dexamethasone short term treatment for
brain edema or spinal cord edema
Unknown; 43 days; 32 days Unknown; 2813 mg; 2533 mg None
Snyder et al. [120] 2 Femoral head PO Hydrocortisone 60 mg/day; Hydrocortisone
30–50 mg/day
? Months–1 year Unknown None
Williams et al.
[121]
2 Multi; humeral head;
femoral head
PO Prednisolone 2–20 mg/day; cortisol
5–12 mg/day
18 months; 14 months 2–7 g of prednisolone; 8 g cortisol Addison's
Hendry [122] 1 Femoral head NA NA NA NA NA
Watkins [123] 1 Femoral head PO Prednisolone 60 mg×14 days q
6 weeks×6 courses
Prednisolone 60mg×14 days
q 6 weeks×6 courses
NA Hodgkin's
McCluskey
et al. [124]
3 Bilateral femur/
humeral head
PO Hydrocortisone for brain edema. After
first 32 days, started on 7–9 mg prednisone
per day; dexamethasone for brain edema;
dexamethasone for spinal cord injury
High dose for 32 days and then
7–9mg for 7 months; 18 days;
37 days
Dexamethasone 191mg equivalent
for first 32 days and additionally
1680mg prednisone over 7 months;
dexamethasone 216mg;
dexamethasone 172mg (2953 mg;
1440mg; 1146mg of pred)
None
Anderton et al.
[125]
1 Bilateral humeral head PO Dexamethasone 4 mg po 6 h 1 week 1120 mg None
Black et al.
[126]
4 Patient 1: bilateral femoral
head, bilateral humeral head,
right tibial plateau; patient 2:
bilateral hip, shoulders, right
wrist; patient 3: bilateral
femoral and left humeral
head; Patient 4: Bilateral
femoral heads
PO Dexamethasone for brain edema or
spinal edema (daily doses not described)
Patient 1: 24 days; patient 2:
20 days; patient 3: 30 days;
patient 4: 15 days
Patient 1: 136mg dexamethasone;
Patient 2: 217mg; Patient 3: 165mg;
Patient 4: 140mg (906mg; 1446 mg;
1100mg; 933mg of pred)
None
Richards et al.
[127]
6 Femoral Head PO 1. Prednisone 10–30/day 2. MPSL
12–36 mg/day 3. Prednisone 40–80 mg/day
4.Prednisone 10–40 mg/day 5. MPSL
8–32 mg/day 6. Prednisone 5–20 mg/day
1. 20 years 2. 15 years
3. 6 weeks 4. 15 years
5. 3.5 years 6. 2 years
NA None; patient # 6
ethanol abuse,
polycythemia
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Interpreting data from case reports must be undertaken carefully.
Gleaning information regarding the effect of exact steroid dose,
duration, cumulative dose–risk relationship or preparation on the
development of osteonecrosis must be interpreted within the context
of confounding factors within a patient. The pathogenesis of
osteonecrosis is indeed likely related to a multi-hit theory in a
predisposed host. In addition to the type and dosage of steroids, the
underlying condition, other concurrent medications, and lifestyle
variables such as alcohol and cigarette smoking are likely to be
confounding variables. Furthermore, given the volume of prescrip-
tions for intraarticular (IA), intramuscular (IM), topical, oral and
inhaled steroids, low numbers of isolated case reports needs to be
interpreted within the context of the individual patient's history.
Finally, the sheer variety of preparations and dosing, which are
potentially prescribed by multiple physicians throughout a patients'
lifetime, make calculating and tallying the exact cumulative dose of
steroid difficult and fraught with potential error. A list of predisposing
risk factors for osteonecrosis is shown in Table 2.
In all, 66 case reports consisting of 1 to 6 patients were identified
and included in Table 3. These patients had a wide range of diseases,
including idiopathic thrombocytopenic purpura, polycythemia, Addi-
son's, nephrotic syndrome, inflammatory bowel disease, alcohol
abuse, renal transplant, autoimmune inflammatory disease (SLE,
MCTD, dermatomyositis, polymyositis, rheumatoid arthritis and
psoriasis), malignancy (breast cancer post radiation, Hodgkin's
lymphoma, bone marrow transplantation, acute lymphocytic leuke-
mia, and bronchogenic carcinoma), asthma, allergic rhinitis, neuro-
surgical patients, myasthenia gravis, and pregnancy. The femoral head
was the most commonly involved site, occurring in 54/85 patients,
followed by the knee, humeral head and ankle. The most commonly
associated administered route included intravenous (IV) pulse
steroids, followed by oral, and rare reports of intramuscular depot
(n=5), topical (n=5) intraarticular (n=4), inhaled (n=4), and
enema (n=1) steroid induced osteonecrosis.
Single dose steroid (IM or IA) and subsequent risk of osteonecrosis
are of particular concern and were examined. This was found to be
uncommon with only 2 case reports of isolated IM or IA injection and
subsequent osteonecrosis [12,13]. The remainder of reported IA/IM
associated cases includes concurrent or subsequent addition of other
steroid routes of administration (inhaled, oral, pulse, topical, and
repeated IA/IM injections). Interpretation of case reports of osteone-
crosis linked to topical steroids was limited. Of the 5 described cases, 4
were treated with long term topical preparations from 2 to 20 years
with rough cumulative doses ranging widely from 1 to 15,000 mg
prednisone equivalent. The majority of cases were also treated with
additional preparation(s) of oral or inhaled steroids. Thus, osteone-
crosis is likely to be an exceedingly rare phenomenon with topical
steroids alone and is more likely to occur after prolonged therapywith
cumulative doses and concurrent use of additional steroid therapy
preparations. The risk of osteonecrosis from inhaled steroids is of
concern given the vast number of steroid inhalers prescribed for
asthma. In theory, the cumulative dose of inhaled steroid over a
lifetime could add up to sizeable amounts. However, conclusions
regarding steroid risk are again difficult to draw from the 4 reported
cases related to inhaled steroids [14–17] because all cases were
concurrently or subsequently treated with oral steroids prior to the
diagnosis of osteonecrosis. Though no studies have been performed,
the recent unapproved but commonplace use of swallowed ultra high
dose inhaled steroids (specifically fluticasone dipropionate) to treat
eosinophilic esophagitis will increase the risk of osteonecrosis in these
patients.
Themajority of case reports involved high dose pulse steroids with
dexamethasone or methylprednisolone, followed by varying dura-
tions of oral steroids on a daily or repetitive basis. The cumulativedose was described in most reports (45/66), and ranged from 150 to
445,000 mg of prednisone equivalent (average 5969 mg prednisone).
Approximately 1000 mg of oral prednisone administered within a
short window will place patients at increased risk. Any addition of
parenterally administered steroids, further increases this risk signif-
icantly. Parenterally administered steroids are often discussed in
terms of their serum half-life but one should remember that the
biologic half-life of the drug can often significantly exceed its serum
half-life.
8. Risk of steroid induced osteonecrosis in patients with systemic
lupus erythematosus
Systemic lupus erythematosus is a multi-organ, multisystem
autoimmune disease for which steroids are an essential aspect
of therapy. Steroid induced osteonecrosis in SLE is well established
[18–20] and is clinically apparent in 4 to 15% of patients, but rises to
nearly 40% when asymptomatic, image-proven osteonecrosis is taken
into account [21]. Typically SLE patients have multi-joint onset of
osteonecrosis, the hips being the most common site, followed by the
knees and shoulders [22]. The goal of this amalgamation of
prospective, retrospective and cohort studies is to try and establish
a pattern of risk of steroid dosing and development of osteonecrosis in
SLE patients. A summary of these studies is presented in Table 4.
8.1. Cushingoid habitus and steroid dose
A cushingoid appearance tends to occur with higher or longer-
term dosing of steroid therapy. 5/20 studies specifically noted the
correlation of cushingoid appearance and development of osteone-
crosis. Mont et al. [34], studied clinical and laboratory factors in
patients with systemic lupus erythematosus to identify subgroups at
higher risk for developing osteonecrosis. 31 out of 103 (30%) patients
studied with SLE developed osteonecrosis and were found to have
significant increases in cushingoid body habitus (74% with vs. 42%
without, p=0.002), thrombophlebitis, vasculitis, cigarette smoking,
and preeclampsia. Similarly, Gladman et al. [23], Mok et al. [24],
Massardo et al. [25] and Zizic et al. [22] found a statistically significant
correlation between osteonecrosis and cushingoid appearance (OR
3.8 in Gladman study). However, osteonecrosis can exist in SLE in the
absence of cushingoid features.
8.2. Maximum daily dose/pulse therapy
The dose of steroid influences the risk for developing osteone-
crosis. In the studies compiled, 16/20 specifically recorded and
addressed daily dosing of corticosteroid. Out of these 16 studies, 6
studies did not find a statistically significant correlation between daily
steroid dosing (mean or maximal daily dosing) and the development
of osteonecrosis [26,27]. Interestingly, the majority of the negative
association occurred in papers prior to 1978 [19,28–30]. In 1960,
Dubois et al. [28] was the first to recognize a connection between SLE
and development of osteonecrosis. However, he did not find a
relationship to steroid dosing and occurrence, probably because
patients had received high doses and the study was done before MRI.
Similarly, in 1974 and 1976, Bergstein et al. [19] and Smith et al. [30],
respectively, found no correlation between daily steroid dosing and
osteonecrosis. In 1978, Diamant et al. [29] failed to find a correlation
between peak dose, duration or cumulative dose of steroid and
osteonecrosis. However, since then, only 1 further study in 2010 by
Nakumura et al. [26], echoed this negative correlation. The authors of
this study concluded that there is no statistically significant difference
in the highest daily dose of steroids in osteonecrosis and non-
osteonecrosis groups (p=0.072), though the p-value did approach
significance. A major criticism of this study is that methylprednisolone
Table 4
Prospective, retrospective, case control studies of steroid induced osteonecrosis in SLE.
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment
duration
Cumulative dose (steroid
equivalent in prednisone)
Site of lesion Remarks
Uea-areewongsa
et al. [35]
Retrospective
Case control
41/186
only 20 patient included in
data analysis
NA NA NA Use of steroids (recorded as evidenced by
maximum and mean daily prednisolone dose)
was significantly higher in the ON group than
in controls
Nakamura et al.
[26]
Prospective 169 pts
ON in 260 of 676 pts (38%)
Pediatric: 4/72 joints (6%)
Adolescent: 49/100 joints (49%)
Adult: 207/504 joints (41%)
The mean highest daily corticosteroid
dosages were 51.4, 60.4, 57.4 mg/day
in pediatric, adolescent, adults, respectively.
The mean highest daily corticosteroid
dosage according to body weight was
1.5 mg/kg/day (range 0.7–3.0) in
pediatric patients, 1.2 mg/kg/day
(range 0.6–2.0) in adolescent patients,
and 1.1 mg/kg/day (range 0.4–1.9) in
adult patients. (P=0.0001).
NA NA Hips and knees Rate of ON and mean highest daily steroid
dose significantly lower in pediatrics vs.
adolescent and adult (pb0.0001)
However: Highest daily dose of steroid not SS
different in +AVN vs.−AVN in mean daily
dose (P=0.072) and according to body
weight. (P=0.820)
Limitations: MPSL pulse therapy not studied
or reported
Jaovisidha [37] Prospective 2/11 NA NA 4920 mg NA The 2 AVN patients had longest duration
of steroid treatment before MR study (105
and 99 days) and higher cumulative dose
of prednisolone compared to non-AVN
patients.
Gladman et al.
[36]
Retrospective
Case control
95/744 Maximum daily dose in +AVN/−AVN:
44.4/28.1 mg
NA IN +AVN/−AVN: 23.1/15 g Hip most
common
AVN significantly associated with the use
of CS (OR=19), maximal dose of steroids
(OR=1.02), cumulative dose (OR=1.04)
and duration of therapy (OR=1.15);
however, in the multivariate analyses, only
the use of corticosteroids remained
significantly associated with osteonecrosis
(OR=18.5).
cushingoid appearance OR 3.8
Oinuma et al.
[27]
Prospective 32/72 (44%) 40mg/day or more equivalent
prednisolone
The initial mean (SD) CS dose 58.2
(10.1)/58.6 (16.6) mg/day in the
+AVN/−AVN
17 pts in ON group 18 in non-ON
group treated with MPPT
AVN onset after
39.6 and 100.2
days of treatment.
NA Multi-joint Early development of ON in SLE was related
to an event just after high dose CS treatment,
and was not related to the total treatment
period, the highest daily dose, a continuous
high dose, or the cumulative dose of
corticosteroid.
SLE ON lesions developed very early
(1–2months) after starting high dose CS
treatment.
Zonana-Nacach
et al. [32]
Retrospective 47/539 (8.7%) Prednisone high dose (N60mg/day for
N2months) in 21% of total cohort
Pulse MPSL (1–3 g IV) in 30% of
total cohort
NA Converted to relative risk. NA The risk significantly increased with exposure
to a high dose of prednisone. Each 2 mo of
exposure to N60mg of prednisone was
associated with 1.2-fold increased risk for
development of AVN
Risk was not associated with cumulative dose
or pulse therapy
Mok et al. [24] Retrospective 38/143 (26%) NA NA AVN+ vs. AVN− in 1 and 4month
cumulative dose:1.8 vs. 1.1 and 4.5 vs.
2.8 g, respectively; Pb0.01 in both
NA Highest cumulative prednisolone dose in 1
and 4 mo was significantly higher in SLE
patients with ON vs. without ON (1.8 vs.
1.1 and 4.5 vs. 2.8 g, respectively).
+Correlation with cushingoid habitus
and ON
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Table 4 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment
duration
Cumulative dose (steroid
equivalent in prednisone)
Site of lesion Remarks
Mont et al. [34] Cohort 31/72 (43%) Mean maximal prednisone dose was
60 vs. 37 mg for SLE patients +AVN
vs.−AVN
NA NA NA SLE pts with osteonecrosis had significant
increases in cushingoid body habitus and
higher maximal prednisone doses compared
with SLE patients without osteonecrosis.
Rascu et al. [38] Retrospective 6/280 (2.1%) Mean daily dose 21.3 mg
Max daily dose 72 mg
NA Mean cumulative dose 38,614 mg
IV MPSL in 2/6
Hip most
common
+Correlation between steroid dose and
development of AVN, BUT other factors likely
play role as well.
Drawbacks: only analyzed symptomatic ON
Migliaresi et al.
[33]
Prospective 7/69 (10%) NA 3–12 month Total corticosteroid dose including
MPSL therapy in +AVN vs.−AVN
was 20.6+/−14.9 g vs. 29.1+/−29 g
Total corticosteroid therapy in those
not treated with MPSL pulse therapy
in AVN+ vs.
−AVN was 20.6+/−14.9 vs.
15.8+/−17.7
NA +Relationship between AVN and
conventional CS treatment.
No increased risk of AVN in MPPT-treated
patients, even though they cumulated the
highest CS doses.
Shortcomings: study might have
underestimated the true occurrence of AVN
because it was performed by radiographs
and/or bone scan and in the follow up it
included only symptomatic AVN.
Massardo
et al. [25]
Retrospective Total 17/176
Group A (MPSL):
7/36 patients (19%)
Group B (no MPSL):
10/154 (6%) patients
Pb0.04
Group A: pulse methylprednisolone
Group B: no pulse methylprednisolone
Steroid doseN40mg/day in 1st month:
57%/37% in AVN+/AVN−
NA NA Femoral head
most common
Patients who developed AVN received a higher
dose of steroid in a shorter period of time.
+Correlation with +AVN and cushingoid
appearance, use of MPSL (Pb0.045), steroid
doses N or =40mg/day during the first
month of treatment, a ratio of steroid dose
in grams/year N or =12
SS only with MSPL and cushingoid
appearance
Ono et al. [31] 5 year
prospective
study
9/62 total patients (14%) Prednisone/MPSL at dose
of N30 mg/day
N1 month NA NA Both IV pulse CS and oral prednisolone
therapy at a dose N30mg/day for at least
1 month were risk factors for ON.
However, it is unclear whether short term
high dose MPSL pulse therapy is a risk factor.
Weiner et al.
[39]
Retrospective 28/172 (16.3%) Prednisone/MPSL NA NA CS intake during the first 1.5 years after
diagnosis of SLE and during the third year
after diagnosis was significantly greater for
the patients AVN+ vs. AVN−.
Felson et al.
[21]
Metanalysis
of 22 studies
(SLE, renal
transplant,
BMT, Hodgkin's)
AVN range 0–31% 1st month, 3 months, 6 months, and
12months (total steroid/oral steroid),
respectively was
127/80, 74/50, 49/34, 29/25.
1-, 3-, 6-, and
12-month periods
NA NA +Relationship between oral dose in each
time period and development of AVN
Comparing steroid dose and bolus steroids
indicated that a 9000 mg prednisone
(equivalent) cumulative dosage given in a
month had a 22% incidence of AVN.
Bolus dose was not associated with AVN.
This quantitative review strongly suggests
that steroid dose is the major predictor of
the risk of AVN.
The oral dose effect amounts to a 4.6%
increase in the risk of AVN for every 10
mg/day rise in oral steroids during the
first 6 months of therapy
Draw backs: only a small number of non-
renal cohorts in study (SLE patients have
different risks!)
(continued on next page)
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Table 4 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment
duration
Cumulative dose (steroid
equivalent in prednisone)
Site of lesion Remarks
Zizic et al.
[22]
Prospective 28/54 total patients (52%)
3/6 patients on MPSL
developed AVN
The mean daily dose of prednisone for
the highest month of therapy was
N40 mg/day in 93% and N20mg/day
in all patients with ischemic necrosis
of bone.
NA NA Multifocal Cushingoid changes in 24 (86%) of the 28
patients with AVN vs. 4 (15%) of the 26
patients without AVN (pb0.0001).
The duration of steroid therapy, total
cumulative steroid dose, and the mean
daily prednisone dose for the first 1–12
months of therapy were not significantly
different between the two groups.
Mean daily prednisone dose for the highest
single month as well as the highest
consecutive three, six, and 12months of
therapy was significantly higher in patients
with ischemic necrosis of bone.
A lower mean dose of prednisone was
required to produce ischemic necrosis of
bone in patients with Reynaud's phenomenon.
Abeles [40] Retrospective 17/365 (4.7%) NA 1, 3, and 6months
Average duration of
therapy 4.3 years
Mean total dose in first 1,
3, and 6 mo in +AVN vs.
−AVN: 1.4 vs. 0.6 g; 3.5 vs.
1.9 g; 6.4 vs. 3 g
NA Severity of disease and duration of therapy
were not found to correlate with AN.
High initial corticosteroid dosages in
patients with SLE seem to be associated
with the development of AN.
Dimant et al.
[29]
Retrospective
Case control
22/234 (9%) NA NA NA NA No correlation was found with duration,
peak dose, or cumulative dose of
corticosteroid therapy.
Smith et al.
[30]
Retrospective
case control
7/99 (7%) Patients with AVN:
11.88 mg prednisone
Patients without AVN:
14.18 mg prednisone
Patients with AVN:
19.86 months
of treatment
22.86 months of
treatment
Patients with AVN: 13.83 g
prednisone
Patients without AVN 18.18 g
prednisone
NA No correlation between steroid dose and AVN.
Bergstein
et al. [19]
Prospective 14/35 Prednisone 2mg/kg
per day in divided doses.
Following remission of
activity prednisone was
“tapered.”
NA NA Most common
site distal femur
No difference was found in the age of
onset of SLE, the duration of prednisone
or the average annual dose of prednisone
between patients with and without bone
disease.
+Correlation with total cumulative dose
up until dx of ON
Dubois et al.
[28]
Retrospective 11/400 NA NA NA NA No association of AVN with steroid therapy
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731C. Powell et al. / Autoimmunity Reviews 9 (2010) 721–743pulse therapywas not reported or included in the data analysis andmay
have in turn, led to this negative conclusion.
Since 1978, the evidence is clear that there is a correlation
between mean daily dose, maximal daily dose or high dose steroid
therapy and the development of osteonecrosis. Massardo et al. [25],
found a positive correlation with osteonecrosis and the use of
prednisone doses greater than or equal to 40 mg/day. He further
noted that high dose methylprednisolone therapy was also a risk
factor and concluded that patients who developed osteonecrosis
received a higher dose of steroid in a shorter period of time compared
with those who did not develop osteonecrosis. Clearly, a lower dose
of prednisone administered over a longer time would carry com-
parably increased risks. Statistical significance was reached with the
MPSL data, but not the prednisone data. Ono et al. [31], found that
both IVMPSL pulse therapy and prednisone N30 mg/day for at least a
month were risk factors for osteonecrosis. Zonana-Nacach et al. [32]
also demonstrated that the risk of osteonecrosis significantly
increased with exposure to high dose oral prednisone. He found
that each 2 months of exposure to N60 mgprednisonewas associated
with a 1.2 fold increased risk for development of osteonecrosis. In the
meta-analysis by Felson et al. [21], there was a positive relationship
between oral prednisone dose when evaluated at time intervals of 1,
3, 6, and 12 months, and the subsequent development of osteone-
crosis. The authors suggested that steroid dose is the major factor in
predicting the risk of osteonecrosis. The oral dose effect amounts to a
4.6% increase in the risk of AVN for every 10 mg/day rise in oral
steroids during the first 6 months of therapy. Interestingly, they
found no association if only a single bolus dose of steroids was used.
In 2000, Oinuma et al. [27], found that osteonecrosis development
occurred after high dose corticosteroid treatment, but was not
related to highest daily dose. Migliaresi et al. [33] did not find an
increase in osteonecrosis in methylprednisolone treated patients,
even though they accumulated the highest dose. Mont et al. [34]
found that SLE patients with osteonecrosis received higher maximal
prednisone doses than those without osteonecrosis. Uea-aree-
wongsa et al. [35] found that the use of steroids (recorded as
maximum and mean daily dosing) were significantly higher in the
osteonecrosis group compared to control. Gladman et al. [36]
concluded that osteonecrosis was significantly associated with the
use of steroid (OR=19), and correlated with the maximal dose of
steroids per day (OR=1.02). In a multivariate analysis, only the use
of steroids was statistically significant. Finally, themean daily dose of
prednisone for the highest month of therapy was N40 mg/day in 93%
and N20 mg/day in 100% of patients who developed osteonecrosis
[22]. The mean daily prednisone dose for the highest single month of
treatment, as well as, the maximal dose during consecutive 3, 6,
12 months of therapy was significantly higher in patients with
osteonecrosis [22]. This study reflects that higher daily dosing has a
positive correlation to osteonecrosis development.
8.3. Cumulative dose
The correlation of higher cumulative dose and development of
osteonecrosis has also been studied. In all, 13/20 SLE studies
commented on cumulative dosing. Out of these 13 studies, 5 studies
did not find an association with cumulative dosing [20,21,36–39],
while 8 studies did [19–21,25,36,37,39,40]. With regard to positive
correlation, Mok et al. [20] identified 38/143 subjects with osteone-
crosis and found that the cumulative dose at 1 and 4 months was
significantly higher in the SLE patients with osteonecrosis vs. without
osteonecrosis (1.8 vs. 1.1 at 1 month and 4.5 vs. 2.8 g prednisone at
4 months). Jaovisidha et al. [37] found that the 2 patients who
developed osteonecrosis had the longest duration of corticosteroid
treatment and higher cumulative dose compared to the patients who
did not develop osteonecrosis, but this was a small cohort of patients
and limited conclusions can thus be drawn from it. In a retrospective,case control series, Gladman et al. [23] identified 95 patients with
osteonecrosis out of a total of 744 SLE patients. Data analysis
determined a minimally positive odds ratio of 1.04 for cumulative
dose, which did not reach statistical significance. Weiner et al. [39],
found that corticosteroid intake during the first 1.5 years after
diagnosis of SLE and during the third year after diagnosis of SLE was
significantly greater in the osteonecrosis vs. non-osteonecrosis group.
Felson et al. [21], was the only metanalysis available and looked at 22
different studies with underlying disorders including renal transplant,
SLE, BMT, and Hodgkin's disease. Limited conclusions can be deduced
with respect to SLE and steroid dose as only 3/22 studies looked at an
SLE cohort. When Felson et al. [21], compared steroid dose and bolus
steroids, they calculated that a 9 g prednisone equivalent cumulative
dosing given in a month had a 22% incidence of osteonecrosis. Further
discussion of this paper will be included in subsequent sections as it
applies. Massardo et al. [25] noted a positive correlation with
osteonecrosis when patients were treated with a cumulative dose
of ≥12 g/year. Finally Bergstein et al. [19], similarly found a positive
correlation with cumulative dosing. Overall, the data indicates a
correlation between higher cumulative dosing and increased risk for
osteonecrosis.9. Risk of steroid induced osteonecrosis in renal
transplant patients
It is in renal transplant patients that the association of corticoste-
roid induced osteonecrosis was first described [3]. Those with years of
chronic renal failure and osteodystrophy are particularly prone to
steroid induced osteonecrosis. Between 3 and 40% of renal transplant
patients suffer from osteonecrosis, but fortunately there has been a
decrease in the prevalence with improvement in dialysis maintenance
care. There have been numerous studies examining the relationship
between steroid use in transplant patients and the development of
osteonecrosis. Of particular interest is the relationship between daily
dosing, high dose pulse therapy, cumulative dose and the risk of
osteonecrosis. 24 pertinent studies were reviewed and are outlined in
Table 5.9.1. Daily dose
18/24 studies selected looked directly at daily steroid dosing as a
potential risk factor of osteonecrosis. 5/18 found no statistically
significant relationship to osteonecrosis risk [41–44]. Interestingly, as
seenwith the SLE studies, the negative relationship, was only found in
studies that were greater than 25 years old. Since then, there has been
repeated and dramatic evidence of a dosing relationship to risk. In
2008, Shibatani et al. [45], performed a retrospective analysis of 150
renal transplant patients, 37 of whom developed osteonecrosis. The
authors found a statistically significant dose–response association at
8 weeks after transplantation. Considerable correlation with cumula-
tive dose was found as will be described in the next section. The
finding of significantly higher daily dose and risk was echoed in
multiple studies [21,46–50]. Koo et al. [7], found that high dose steroid
during the first several weeks was more important that total
cumulative dose. Patton et al. [49], noted that the mean linear trend
of higher daily prednisone dose was also statistically significant
(pb0.03) for the development of osteonecrosis. In contrast to the SLE
data, the majority of studies (17 of 22) in the Felson metanalysis were
renal transplant studies. Overall, the general consensus among these
studies is that a higher daily dose confers a significant risk for
developing osteonecrosis. Unfortunately, due to the variation among
studies, a recommendation for a universally “safe” steroid dose cannot
be made and in all situations, physicians should exercise caution in
using steroids and provide appropriate informed consent.
Table 5
Prospective, retrospective, case control studies of steroid induced osteonecrosis in renal transplant patients.
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Shibatani
et al. [45]
Retrospective 37/150 (24%) MPSL 500 mg IV during
surgery, PSL 50mg from
the day after surgery,
divided into 3 doses a
day×7 days (March
1989–Nov1996) or for
3 days (after Dec 1996).
After that, PO dose
gradually reduced to 40,
30, 25, 20, and 17.5 mg
every 7 days, and
maintenance dose of
10 mg was attained by
the 6th week.
In acute rejection: IV MPSL
2–8 weeks The steroid doses (lower,
middle, and upper thirds)
at 2-week period: b550,
550–650, and N650 mg,
respectively.
At 4-week period: b895,
895–1130, and N1130mg,
respectively. At 6-week
period: b1165, 1165–1488,
and N1488mg, respectively.
At 8-week period: b1400,
1400–1795, and N1795mg,
respectively
MPSL bolus in 24 pts at an
average dose of 3111mg
N/A SS association between AVN incidence
and the total dose of steroids in the first
2 months after transplantation, and there
was a dose–response relationship.
In the 2-week period after transplantation,
odds ratios for AVN in the middle and
upper-dose steroid groups rose, though
not statistically significantly.
In the 4 and 6-week periods after
transplantation, ORs for the middle-
dose group rose significantly and those
for the upper-dose group also rose, but
not significantly.
In the 8-week period after transplantation,
ORs for the middle- and upper-dose
groups rose significantly, and a significant
dose–response relationship was observed.
Hedri et al.
[51]
Retrospective 15/326 (4.6%) MPSL 1–2 mg/kg/day. CS dose
gradually reduced over the
next 8–12 weeks to a
maintenance of 10–15mg/day.
AVN diagnosed at a
mean of 3.5 years after
RT (range, 0.5–13 years)
Cumulative mean dose in
AVN group 24,240mg+/−
16,450 vs. 14,243+/−7530
in non-AVN group (P=0.04)
Hip Cumulative CS dose and the acute rejection
rate were higher among the AVN group
than the control group (P=0.04 and
P=0.058, respectively).
Koo et al.
[7]
Retrospective 22 total Renal transplant
(7), aplastic anemia (6)
nephrotic syndrome (3)
liver transplantation (1),
Crohn's (1) eosinophilic
granuloma in (1), pemphigus
vulgaris (1), MS (1), ALL (1)
During 1st month mean
daily dose was 76 mg
(range 60–145 mg)
The duration of steroid
treatment within this
period (mean 4.5 months).
Start of steroid treatment
to the diagnosis by MRI
mean 5.3 months
1800–15,505mg (mean 5928mg).
During 1st month: mean dose
2267mg
Until the diagnosis on magnetic
resonance imaging, the total dose
of steroid mean 5928mg
Femoral head,
other
The high dose of steroid during the first
several weeks seems to be more important
than the total cumulative dose.
Tang et al.
[46]
Retrospective
Case control
16/397 (4.2%) control group
31
NA NA IV MPSL cumulative dose in 1st
year in +AVN vs.−AVN: 2.97+/−
2.48 vs. 1.42+/−2.01 (P=0.026)
NA Significantly higher body weight increments,
rejection rate, mean daily oral prednisolone,
and cumulative intravenous pulse
methylprednisolone consumption in the
first posttransplant year in AVN group
Saisu et al.
[128]
Group A: 27%
Group B: 100%
b3 months Group A: 0–4000mg corticosteroid
Group B: N4000mg IV
methylprednisolone
Femoral head
Bradbury et
al. [53]
Retrospective 3% NA NA MPSL at 1 month in AVN+/
AVN−:5371/
2610 mg ( P=0.0005)
MPSL at 1 year in AVN+/AVN−:
6171/2966 mg
Cumulative prednisone at 1 year
was 5435 vs. 4540 for AVN− vs.
AVN+
NA +Association between cumulative doses
of IV MPSL in the first month after
transplantation and the onset of
osteonecrosis.
No association between the cumulative
doses of prednisone during the first year
after transplantation and the development
of osteonecrosis
Tervoven et
al. [47]
Prospective 6/100 (6%) NA N6months mean time of
exposure for AVN+ 9.5
years
Mean time of exposure for
AVN− 8.1 years
Mean 32.1 g for all comers
Mean for AVN+ 40.9 g
(p=0.269)
HIP No significant differences were found
regarding the total dose of corticosteroids
and AVN, but a trend towards higher dose
and development of AVN was evident
Lausten et
al. [48]
Retrospective Group 1 (high dose steroid):
42/374 (11%)
Group 2 (low dose steroid):
19/376 (5%)
p=0.002
34 mg/day
17 mg/day
Mean interval between
treatment and ON—26
months in first group
21months in second group
Average prednisone during 1st
month, 1st year
Group 1: 4224, 12,540 mg
Group 2: 1712, 6481 mg
NA Higher incidence with increased daily
and cumulative dose of steroid
The incidence of femoral head AVN was
more than halved with reduction of
cumulative steroid from 12 g to 6.5 g
732
C.Pow
ell
et
al./
A
utoim
m
unity
Review
s
9
(2010)
721
–743
Table 5 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Patton et al.
[49]
Retrospective 52/444 (16%) NA NA ON was associated with a history of early
acute rejection (p less than 0.02), higher
final serum creatinine (p=0.07), and
greater mean prednisone (pb0.0001).
The mean linear trend of daily pred dose
was also significant (pb0.03)
Felson et al.
[21]
Metanalysis
of 22 studies
AVN range 0–31%
(SLE, renal transplant,
BMT, Hodgkin's)
1st month, 3 months, 6 months,
and 12 months (total steroid/
oral steroid), respectively was
127/80, 74/50, 49/34, 29/25.
1-, 3-, 6-, and
12-month periods
NA NA +Relationship between oral dose in each
time period and development of AVN
Comparing steroid dose and bolus steroids
indicated that a 9000 mg prednisone
(equivalent) cumulative dosage given in
a month had a 22% incidence of AVN.
Bolus dose was not associated with AVN.
This quantitative review strongly suggests
that steroid dose is the major predictor of
the risk of AVN.
The oral dose effect amounts to a 4.6%
increase in the risk of AVN for every
10 mg/day rise in oral steroids during
the first 6 months of therapy
Draw backs: only a small number of
non-renal cohorts in study (SLE patients
shave different risks!)
Metselaar
et al. [50]
Retrospective 61/248 (24%) Prednisone 30mg/day after
transplantation
Rejection episodes treated
with MPSL or increasing oral
prednisone
NA NA Hip, knee, ankle,
shoulder, elbow
Cumulative dose of steroids was not
predictive of AVN
Increase in body weight showed a strong
correlation with AVN development at
6 months
Haajanen
et al. [54]
Retrospective 29/546 (5.3%) Until 1975, initial MPSL was
100–160 mg/day, where after
68–80 mg/day
MPSL 1 month after transplant:
44–60 mg/day; 6 months after:
12–36 mg/day; 12 months after:
0–20 mg/day
Rejections treated with IV MPSL
0.5–1 g/day (total 2–5 g)
NA Total steroid without pulse at
12 months in +
AVN/−AVN: 7716/7490
Total steroid with pulse doses
at 12 months in +AVN/−AVN:
10,135/8912
Femoral Head No significant difference in +AVN vs.
−AVN in cumulative steroid without
pulse dose group.
Highly significant difference in +AVN/
−AVN in cumulative steroid with pulse
dose (IV MPSL)
Morris et
al. [55]
Prospective 9/72 (12%)
8 patients in HD group
and 1 patient in LD group
High dose (HD) regiment: 100mg
prednisolone daily in two doses
started on the day after
transplantation, reduced to 90 mg
daily after 5 days and then by 5mg
every 5 days to 20mg, after which
the dose was reduced by 1mg
every 2 weeks down to a
maintenance dose of 10 mg/day.
Low dose (LD) regiment: 30 mg
prednisolone daily in divided doses
for 60 days, reduced to 25mg daily
for 2 weeks, and then to 20mg/day.
Subsequently, same taper as HD group.
The LD patients received, in addition,
1 g MPSL IV on days 6, 7, and 8 after
transplantation, and all patients were
given 100mg hydrocortisone i.v.
during the operation.
NA Cumulative dose in HDMPSL
during first 6 months 8560+/−
4500mg; oral prednisone
during first 6 months 6340+/−140
Cumulative steroid in LD group
in first
6 months: methylprednisolone
9200+/−
4000; prednisone 3950+/−110
NA AVN is related mostly to the cumulative
steroid dose received during the first few
months after transplantation.
Problems: low dose group with
methylprednisolone may have actually
gotten more total steroid. Only SS results
were of prednisone data.
(continued on next page)
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Table 5 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Daily dose Treatment duration Cumulative dose Site of lesion Notes
De Graaf
et al. [52]
Retrospective 52/170 (30%) Initial prednisone dose
posttransplant: 80 mg/day, reduced
within 6 days to 25–30 mg/day.
Subsequently reduced each month
by 2.5 mg until min daily dose of
7.5–10 mg was reached.
Rejection: IV MPSL 125–200
mg/day×5 days and then tapered.
Mean prednisone dose in
+AVN:6300+/−990mg
1, 3, and 6 months Total prednisone in first 3
months: 2380–9230 mg
HipNkneeNankle +Correlation between cumulative
prednisone in 1st 3 months and with the
incidence of AVN. (pb0.001)
Statistically significant correlation
between number of rejection treatments
and incidence of AVN
DosagesN5000 mg during first 3 months
appears to be critical dose cut off above
which AVN may develop
Hely et al.
[129]
Retrospective 29 total children; 21% AVN. NA NA NA Femoral head The presence of osteodystrophy prior to
transplant was strongly correlated with
osteonecrosis
Extensive reviews of their records failed to
clearly identify other predisposing factors
Elmsted et
al. [130]
Retrospective
Case control
19 with AVN compared
to 125 without AVN
NA NA NA NA A direct relationship between dose of
steroids and the development of AVN
not consistently demonstrated
Ibels et al.
[41]
Prospective
Case control
40/194 Prednisone 2.5–40mg/day
(mean 15.9)
Rejection treated with MPSL
NA NA Multi sites. Hips
most common.
No significant correlation seen in
prednisone dose and AVN even in patients
treated with MSPL for acute rejection
Potter et al.
[131]
Retrospective
Case control
11/100 (11%) At the time of transplantation,
treatment with prednisone, 2 to 4 mg/kg
The prednisone dose is rapidly decreased
to 0.8 to 1.0 mg/kg at the end of one
month and more slowly thereafter to a
minimum dose of 0.1 to 0.3 mg/kg
Rejection treated with MPSL
b12 months Cumulative prednisone dose at 3,
6, 12, and 24months in +AVN/−
AVN, respectively.
3368/3466, 5018/4211, 8336/8086,
11,893/14,087
Total dose in +AVN/−AVN:
14,207/12,432
femoral heads,
14; femoral
condyles, 12; tall,
two; and carpal
naviculars,
two.
Although the prevalence of AVN decreased
after 1967 coincident with a decrease in
prednisone dose, children with AVN
received the same cumulative prednisone
dose as children in a control group.
Levine et al.
[42]
Retrospective
Case control
16 pts with +AVN
compared with 16 control
Mean daily steroid dose for each of the
first 14 28-day periods after
transplantation was calculated for
each patient.
Exact numbers not described
NA The total dosage of CS received by
each patient with AVN was estimated
in an arbitrarily chosen period of the
first 392 days following transplantation.
Exact numbers not described
Femoral heads,
femoral condyles
and humerus
in 1
No significant difference between
AVN+ and control patients in either
total steroid dose or average daily dose
over the first 392 days following transplant.
Bewit et al.
[43]
Retrospective 13 patients developed AVN NA NA No correlation between steroid dose
and AVN
Pierides
[44]
Retrospective
Case control
11/78 (14%)
11 patients with A.N. were
compared with two control
groups of unaffected renal
transplant patients.
Exact mean not recorded NA Exact mean not recorded NA the cumulative dose of prednisone
received by affected patients during the
first three posttransplant months was
found to be significantly higher than that
for both control groups (P less than
0.05
No significant difference was found between
the daily dose of prednisone received by
affected patients and control group II
Troche et
al. [132]
13/90 patients Prednisolone 50mg/day with gradual
reduction to 10–20mg/day over one year
Rejection treated with high dose
prednisolone
NA NA NA No SS difference in amount of CS received
by 13 patients with osteonecrosis and
unaffected patients over a comparable
period.
Harrington
et al. [133]
Retrospective 18/150 NA N3 weeks Of 50 patients who had received an average
total dose of steroids of 2960mg in the
3-week period after transplant 16
developed AVN
Of 101 patients who had received an
average total dose of steroids of 1180mg
in the 3-week period after transplantation,
only 2 developed AVN
NA Total steroid dose in the 3-week period
after transplantation was an etiological
factor in the development of AVN.
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In renal transplant patients, the cumulative dose is of special
interest as it takes into account the number of renal transplant
rejections and the subsequent administration of high dose pulse
therapy. Patton et al. [49], Tang et al. [46], Hedri et al. [51], andDeGraaf
et al. [52] all noted a statistically significant association between acute
rejection and the onset of osteonecrosis. In 1992, Tervoven et al. [47]
found no statistically significant difference regarding total dose of
glucocorticoids, but noted a trend towards higher cumulative dose
and occurrence. In fact, prior to 1985, Metselaar et al. [50], Potter et
al. [121], Levine et al. [42], and BewickTroche et al. [43] also reported
no predictive correlation between cumulative dose and osteone-
crosis but again this data must be tempered by the methodology
used.
More recently, Shibatani [45] found a statistically significant
association between osteonecrosis and the total dose of steroids in
the first 2 months after transplantation. Hedri et al. (p=0.04) [51],
Lausten et al. [48], Felson et al. [21], Morris et al. [55], De Graff et al.
[52], Pierrides et al. [44], and Harrington et al. [133] all found similar
risk with increased cumulative dose. Several authors demonstrated
evidence for increased risk when specifically considering cumulative
IV methylprednisolone [21,46,53–55]. Lausten et al. [48], calculated
that the incidence of femoral head osteonecrosis was more than
halvedwith reduction of the cumulative steroid from 12 g to 6.5 g. De
Graff et al. [52], found that a cumulative dose greater than 5000 mg
during the first 3 months was a striking risk. Bradbury et al. [53]
found a similar association between steroids used during the first
year and subsequent risk of osteonecrosis. In 2002, Koo et al. [7],
noted that daily oral dosing was more important than cumulative
dose. In summary, the majority of the data on renal transplant-
induced osteonecrosis indicates a positive role on cumulative dose
and osteonecrosis development. Multiple confounding variables are
at play here (i.e. active inflammation during rejection may predis-
pose to osteonecrosis, MPSL vs. oral cumulative dosages may confer
different risks).
10. Risk of osteonecrosis in other conditions
The risk of steroid induced osteonecrosis in bone marrow
transplant, cardiac transplant, lung transplant, liver transplant,
acute leukocytic leukemia, Hodgkin's disease, multiple myeloma
undergoing chemotherapy, SARS, multiple sclerosis, and neurosur-
gical patients is noted in Table 6. This third grouping of studies
consists of non-renal transplant patients (bone marrow transplant,
n=6; liver transplant, n=2; cardiac/pulmonary transplant, n=2),
malignancy (Hodgkin's, n=3; acute lymphoblastic leukemia, n=9,
multiple myeloma, n=1), aplastic anemia (n=3), SARS (n=2), and
neurosurgical disorders (n=2). Organ transplantation inevitably
requires steroids for rejection prevention and subsequent osteone-
crosis has been a rare, albeit, well-documented phenomenon found
throughout the literature. In cardiac and liver transplant, an
incidence of 2–3% is suggested by several authors [53,56,57]. This is
much lower than the incidence reported in renal transplant patients
(3–40%) suggesting again that underlying disease has a distinct
influence on the incidence of steroid induced osteonecrosis.
Fortunately over the last 10 years, alternative immunosuppressants
have been increasingly employed, thereby decreasing the overall
need for steroids. Regarding neurosurgical patients, steroids have
shown to be beneficial in cerebral edema, malignancy, meningitis,
cord injury, among others and short courses of high dose corticoste-
roid (often dexamethasone) are usually employed. The overall
incidence of 0 to 0.6% extracted from the scattered case reports and
small studies is considerably lower than the other underlying
diseases discussed thus far [58,59]. With regard to underlying
malignancy and steroid induced osteonecrosis, the incidence varieswidely between 0.6 and 3.4% [60–73]. It is difficult to make
generalized statements regarding steroid dosing with these varied
underlying disorders, but patterns are evident.
10.1. Daily and cumulative dosing in cardiac and liver transplant
In 2 studies of cardiac and liver transplant, Lieberman et al. [56,57],
found no statistically significant relationship between daily prednisone
dosing or IV MPSL and osteonecrosis. The cumulative dosing was also
not statistically different. In 2002, Koo et al. [7], suggested that highdose
steroids during the first several weeks seems to bemore important that
the cumulative dose. The major limitation here is that there was only 1
patient out of 22 that had a solid organ transplant (aside from renal). In
1994, Bradbury et al. [53] performed a retrospective study and found 3%
of cardiac/pulmonary transplant patients developed osteonecrosis. The
author demonstrated a correlation between cumulative dosing of IV
MPSL in thefirst 1 month after transplant and the onset of osteonecrosis
(p=0.005). In summary, there is no significant data to make concrete
statements regardingdosing relationship to osteonecrosis in solid organ
transplant, though clearly there seems to be a trend towards higher
daily and cumulative dose.
10.2. Daily and cumulative dose in malignancy (BMT, ALL, MM, NHL,
and HL)
Talamo et al. [60], found an osteonecrosis incidence of 9% in
patients with multiple myeloma treated with antineoplastic therapy
including steroids. When he adjusted for body weight, cumulative
dose remained significantly associated with osteonecrosis (OR, 1.030;
95% CI, 1.005–1.055, p=0.02). A logistic analysis further predicted
that a cumulative dexamethasone dose of 2880 mg had a 20% chance
of inducing osteonecrosis which was a 4.2-fold higher probability
than a patient treated with a cumulative dexamethasone dose of
800 mg. In acute lymphocytic leukemia (ALL) patients, Arico et al.
[61], found that there was an increased incidence of osteonecrosis
with chemotherapy regiments where the cumulative dosewas higher.
Mattano et al. [63], studied a pediatric ALL population and found a 1.4-
fold increase in osteonecrosis in patients treated with 2 dexameth-
asone pulses as compared to those that received just one. However,
the results did not reach statistical significance. Vaidya et al. [67], also
agreed that the high cumulative doses of steroid were noted to have
an increased risk of osteonecrosis in acute lymphocytic leukemia
patients. In a small cohort of acute lymphocytic leukemia patients,
Chan-Lam et al. [72] reported 5/9 patients with osteonecrosis, which
he proposes may be explained by their protocol of higher dose
steroids (1.5–1.75× greater than in convention chemotherapy).
Several other studies state that steroids play a role in osteonecrosis
development [64,68,74].
In the 5 bone marrow transplant papers, steroid dosing, including
higher cumulative dose, was a significant risk factor for development
of osteonecrosis. In a multivariate analysis, Socie et al. [69], found 5
factors conferring statistically significant risk of osteonecrosis devel-
opment. These factors include chronic GvHD (OR 3.52), acute GvHD
(OR 3.73), ageb16 (OR 5.81), aplastic anemia (OR 3.90), and acute
leukemia (OR 1.72.) The exact steroid dosage was not addressed, but
patients having complications and who are treated with corticoster-
oids, are at increased risk for osteonecrosis. Enright et al. [73] and
Torri et al. [62] echoed these assertions, also finding an increased risk
with acute or chronic graft vs. host disease, higher cumulative steroid
dose, or use of intravenous (IV) pulse therapy.
10.3. Daily and cumulative dosing in neurosurgical patients
The incidence of osteonecrosis in neurosurgical patients was lower
than those with other underlying diseases. This suggests that the
pathogenesis of osteonecrosis involves a “multi-hit” theory, which
Table 6
Prospective, retrospective, case control studies of steroid dosing and osteonecrosis in bone marrow transplant, cardiac transplant, lung transplant, liver transplant, acute lymphocytic leukemia, Hodgkin's disease, Multiple myeloma
undergoing chemotherapy, SARS, multiple sclerosis, neurosurgical patients.
Study/Ref. Study design No. of patients
(+ON/−ON)
Underlying
disease
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Lieberman
et al. [56]
Retrospective 6/204 (3%) Cardiac transplant Three 125 mg doses of IV
MPSL q 12 h starting immediately
after surgical procedure.
On postop day 2, prednisone
70mg/day and then tapered
to 20mg/day by postoperative
day 14.
Taper regimen over the next
180 days down to a maintenance
dose of prednisone 5 mg/day.
For transplant rejection: IV MPSL
bolus of 1500 to 3000mg over
3 days and a bolus of prednisone
770 mg over 16 days.
Most weaned off of steroids
by 1–2 years post op.
Some required continued
maintenance dose prednisone
5mg/day.
Cumulative steroid (MPSL
and prednisone over 2 years)
—in AVN+ 5560 mg; in
AVN− 5866 mg.
Cumulative dose of MPSL at
2 years 881 vs. 1188 in AVN−
vs. AVN+, respectively.
Cumulative dose of prednisone
at 2 years was 4984mg vs.
4372 for AVN− vs. AVN+
N/A No relationship between either the
prednisone or IV MPSL dose and the
development of osteonecrosis of the hip
or knee.
Chan et al.
[75]
Prospective 7/69 SARS prednisolone 0.5–1.0 mg/kg of
body weight daily, or IV
hydrocortisone 100 mg every 8 h
with step-down titration starting
at the third week of admission.
For patients with clinical
deterioration including desaturation
(oxygen saturation, 90% using pulse
oximetry) or development of
new infiltrates in chest radiograph,
pulse steroid using MPSL 0.5 g
daily×3 days
Daily hydrocortisone equivalent
(mg/day) 572 (326–749)
The median hospital-day on
maintenance and/or pulse
CS therapies was 17
Hydrocortisone equivalent
for all corticosteroids (mg)*
9520 (4580–16,600)
N/A Cumulative doses of N2000 mg of MPSL,
N1900 mg of hydrocortisone,
N13,340 mg of hydrocortisone
equivalent, and N18 days on
corticosteroid therapy are
significant risk predictors for
ON, while pulse steroid therapy is not.
Hydrocortisone and
hydrocortisone equivalent not SS
Ce et al.
[134]
Prospective
cohort
5/33 Multiple sclerosis;
tobacco+
N/A N/A Total CS dosage varied
between 10 and 62 g
N/A No meaningful relationship between
dosing and AVN.
Given trends, very high doses of steroids
given in a short-time course constitutes
an independent risk for AVN.
Wong et
al. [58]
Retrospective 4/1352 (0.3%) Neurosurgical
patients
High dose, short course
Dexamethasone
Duration of steroid treatment
ranged from 15 to 27 days
(mean 20 days).
The steroid dose as
dexamethasone
equivalent ranged from 59
to 150 mg (mean 102 mg)
Femoral
head
Though data failed to establish a
relationship between steroid dosage
and the risk of AVN, experience of
long term steroid
management indicates that the
duration and dosage of steroids
are factors contributing to AVN.
Talamo et
al. [60]
Prospective 49/553 Multiple myeloma
undergoing
antineoplastic
therapy
Dexamethasone in 4 phases. N/A The cumulative dexamethasone
dose ranged from 800 to
2880 mg, with a median
cumulative dose to onset of
AVN of 1120 mg.
NA When adjusted for body weight,
the cumulative dexamethasone
dose remained significantly
associated with an increased
probability of AVN (OR, 1.030;
95% CI, 1.005–1.055; P=0.0201).
Higher cumulative dexamethasone
dose (odds ratio [OR], 1.028;
95% CI, 1.012 to 1.044; P=0.0006
[per 40mg of dexamethasone])
A logistic regression equation
predicted that a patient receiving
a cumulative dexamethasone dose
of 2880mg had a 20% chance of
developing AVN, a probability that
was 4.2-fold higher than that of a
patient treated with a cumulative
dexamethasone dose of 800 mg.
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Table 6 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Underlying
disease
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Li et al.
[135]
Retrospective 12/40 SARS N/A average course of treatment
was (24+/−5) days (16 to
30 days).
average total dosage of
methylprednisolone was
(4949+/−2959) mg
N/A The cumulative dosage and duration
of therapy denoted highest risk of AVN
Arico et al.
[61]
Retrospective 15/1421
(1/0.1%)
Chemotherapy in
childhood acute
lymphoblastic
leukemia
N/A N/A AIEOP–ALL-95 regiment:
3250–6420 mg/m2
N/A Cumulative dose is a risk factor
Noted decreased incidence with
comparison between other
chemotherapy regiments
(CCG vs. DFCI) where cumulative
dose is higher (5885–9050 mg/m2
vs. 7600–21,240, respectively)
Koo et al. [7] Retrospective 22 total Renal transplant
(7), aplastic anemia
(6) nephrotic
syndrome (3) liver
transplantation
(1), Crohn's (1)
eosinophilic
granuloma in (1),
pemphigus
vulgaris (1), MS (1),
ALL (1)
During 1st month mean daily
dose was 76 mg
(range 60–145 mg)
The duration of steroid
treatment within this period
(mean 4.5 months).
Start of steroid treatment to
the diagnosis by MRI mean
5.3 months
1800–15,505mg (mean 5928mg).
During 1st month: mean dose
2267 mg
Until the diagnosis on magnetic
resonance imaging, the total
dose \of steroid mean 5928mg
Femoral
head, other
The high dose of steroid during the first
several weeks seems to be more
important than the total cumulative
dose.
Torii et al.
[62]
Retrospective 19/100 (19%) Post-BMT NA NA NA Femoral
head
Four factors were found to be SS
different between patients who had
osteonecrosis develop and those who
did not: younger age at the time of
bone marrow transplantation, chronic
graft-versus-host disease, cumulative
dose of steroid, and intravenous pulse
therapy with methylprednisolone. It
was concluded that a low rate of
complications and low dose steroid
administration would reduce the
incidence of osteonecrosis after bone
marrow transplantation.
Lieberman
et al. [57]
Retrospective 3/203 (2%) Liver transplant MPSL preoperative dose
50–1000 mg of MPSL IV, followed
by a 6-day tapered dose as follows:
day 1, 200 mg; day 2, 160 mg;
day 3, 120 mg; day 4, 80 mg;
day 5, 40 mg; and day 6, 20 mg
IV. On post op day 7, Prednisone
20mg/day×30 days.
Followed by taper of 15mg/day down
to 2.5 mg at 180 days after transplant.
Up to 2 years Prednisone+MPSL at 2 years
in AVN+/AVN−: 9678/10,552
MPSL alone at 2 years in
AVN+/AVN−: 9678/10,552
(mg/m2)
Prednisone alone at 2 years in
AVN+/AVN−: 7,688/7,152
Hip No relationship between either
parenteral or oral steroid dose
and the development
of osteonecrosis of the hip
Mattano et
al. [63]
Retrospective 111/140 (9.3%) ALL-pediatric NA NA (mg/m2)
Induction prednisone: 1815
Delayed intensification
dexamethasone 235 in group A
and B and 470 in group C
Maintenance Prednisone in
males/females: 7000/4400 in
group A and B and 6200/3600
in group C
NA Incidence of ON higher for patients
randomized to receive two 21-day
dexamethasone courses versus one
course (23.2%+/−4.8% vs. 16.4%
+/−4.3%, respectively; P=0.27).
Patients 10–20 years old randomized
to receive DDI (2 dexamethasone
pulses) exhibited a 1.4-fold higher
incidence of symptomatic ON
compared with those who received
SDI (1 dexamethasone pulse), although
this did not reach a conventional
significance level. This effect was
accentuated in females and in those 16
to 20 years of age at diagnosis of ALL.
Conclusion: children ages 10 to 20 years
who receive intensive ALL therapy,
including multiple courses of corticosteroid,
are at significant risk for developing ON.
(continued on next page)
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Table 6 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Underlying
disease
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Ojala et al.
[64]
Prospective 9/24 (34%) ALL Induction phase: prednisone
60 mg/day; delayed intensification
phase, which includes intensive
dexamethasone medication.
4–5 weeks for induction
phase; unclear duration of
intensification phase
Interval between treatment
and osteonecrosis—within a
few months
NA NA Corticosteroids may cause
osteonecrosis in cancer patients.
Wiesman
et al. [65]
Retrospective 17/272 (6%) Post allogenic BMT High dose prednisolone
The mean maximal dose of
prednisolone was 3 mg/kg/day
(range 2–27).
NA Total dose 189 mg/kg
(range 13–555 mg/kg)
The median total dosage of
prednisolone at the time of
diagnosis was 189 mg/kg
(single manifestation
150 mg/kg; multiple
manifestations 313 mg/kg)
with a total range of
13–555 mg/kg.
Femoral
head most
common,
multifocal.
Significant difference in median total
dosage of prednisolone at the time of
diagnosis between single and multifocal
AVN
Enrici et al.
[66]
Retrospective 9/784 (1%) Hodgkin's disease NA Between treatment and
ON—35 months
Prednisone 2725–5250 mg Head of
femur;
1 humeral
head
Osteonecrosis is rare in CS
treated Hodgkin's disease
Wing et al.
[59]
Prospective
cohort study
0/59 Spinal Cord Injury Methylprednisolone 24 h MPSL 11,000–15,000mg
over 24 h
NA Using binomial distribution, we conclude
that the true incidence of AVN among the
methylprednisolone treated group is less
than 5% (a50.05) and therefore continue
to recommend short term (24 h)
methylprednisolone therapy.
Shortcomings: very poor follow up.
Vaidya et al.
[67]
Retrospective 850 (0.6%) ALL NA Duration of chemotherapy
regiment including steroid
24–30months
Between treatment and
ON—29 months
Prednisolone cumulative dose
from 4.5 to 7 g
NA The data suggests that patients
receiving combination chemotherapy,
especially those with high cumulative
doses of steroids, run an increased risk of
developing AVN
Drawback: radiography and bone scans
were performed on symptomatic
patients only.
Fink et al.
[68]
Case control 87/1939 (5%) ALL NA Between treatment and
ON—26 months
NA NA Corticosteroids are a high-risk factor
for developing osteonecrosis in ALL.
Posttransplant steroid use was a risk
factor for the occurrence of AVN
(adjusted OR, 14.4; 95%
CI, 2.8–73.2), with the greatest risk
associated with those receiving steroids
at the time of diagnosis of AVN
(adjusted OR, 31.9; 95% CI, 4.4–248.9).
There was no further increasing
risk associated with increasing duration
of steroid use.
Socie et al.
[69]
Multicenter
retrospective
77/4388 (4%) Post-BMT NA Mean of 15 months
Time delay between steroid
and ON—22months
NA Hip most
often affected
(88%)
In multivariate logistic regression analysis,
five factors remained significantly
associated with an increased risk for
developing avascular necrosis: chronic
GvHD (odds ratio (OR) 3.52), acute GvHD
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Table 6 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Underlying
disease
Daily dose Treatment duration Cumulative dose Site of lesion Notes
(OR 3.73), ageN16 years (OR 5.81),
aplastic anemia (OR 3.90), and
acute leukemia (OR 1.72) Steroids
are part of treatment for GVHD.
Steroids dose and exact relation not
examined. Steroids are a significant
risk factor for developing AVN in post-BMT
patients.
Ojala et al.
[70]
Prospective 9/28 (32%) ALL-pediatric High dose dexamethasone
3 different regiment: all the
regimens included 4–5 weeks of
prednisone at a dose of 60 mg/m2
per day in the induction phase
2/3 regiments with Intensification
phase and high dose dexamethasone
NA NA NA A significant risk of developing AVN exists in
patients on intensive CS treatment for ALL.
All of our patients with AVN had been
treated with IR or HR protocols, which
include a delayed intensification phase with
intensive dexamethasone medication,
whereas no typical AVN were found in the
SR patients, who had not received
dexamethasone
Thornton et al.
[74]
Retrospective
Case series
8/12 patients ALL or NHL High dose dexamethasone
These phases: 28 days of prednisolone
60mg/m 2 body area daily at the
induction phase, 4 weeks of
dexamethasone at 10 mg/m 2 body
area daily at the intensification
phase and 5-day pulses of
prednisolone 10rag daily every
month for 2 years in the
maintenance phase.
NA NA 11 knees,
seven hips, five
shoulders and
five ankles
AVN in these patients is most likely due to
the high dose dexamethasone therapy as in
all eight cases symptoms followed this stage
of the regimen.
Bradbury et al.
[53]
retrospective 5/168 (3%) Cardiac/pulmonary
transplant
NA NA Total MPSL dose at 1 month:
2610mg in patients who did
not develop osteonecrosis
and 5371 milligrams in those
patients who developed
osteonecrosis ( P=0.0005)
Total MPSL at 1 year: 2966mg
vs. 6171mg for AVN− vs. AVN+.
Total prednisone at 1 year:
5435 vs. 4540 for AVN− vs.
AVN+
NA +Association between cumulative doses of
IV MPSL in the first month and 1 year after
transplantation and the onset of AVN.
No association between the cumulative
doses of prednisone during the first year
after transplantation and the development
of osteonecrosis
Socie et al.
[71]
Retrospective 27/727 Post-BMT First line therapy for GVHD was
2 mg/kg×10 days and then tapered
Severe or progressive GVHD was
treated with Prednisone 5 mg/kg
NA Mean cumulative dose
14.3 g/patient (range 2.5–50.5 g).
According to body weight, Mean
total dose of 200mg/kg, range
60–840mg/kg.
Hip most
common
in 69%
3 factors with increased risk for developing
avascular necrosis by multivariate analysis:
male gender (relative risk (RR) 4.72,
P=0.002), age older than 16 (RR=3.87,
P=0.004), and acute graft-versus-host
disease requiring steroid therapy
(RR=6.30, P=0.0002).
Chan-lam et al.
[72]
Retrospective 5/9 (55%) ALL and high grade
malignant Lymphoma
28 days of prednisolone at the dose of
60mg/m2 daily in the induction phase,
4 weeks of dexamethasone at 10mg/m2
daily at the intensification phase and 5-day
prednisolone pulses every month in the
maintenance phase for 2 years.
~2 years NA Hips, knees,
ankles
The relatively high incidence of AVN in our
series could be explained by the dose of
corticosteroids used in the BFM protocol
which is 1.5–1.75× greater than the doses
used in conventional chemotherapy
schedules like the MRC ALL×protocol.
Three out of the four patients who did not
develop clinical AVN did not receive the
late intensification block which contains
high dose dexamethasone and this would
further support the role of high doses of
steroids in causing AVN.
(continued on next page)
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Table 6 (continued)
Study/Ref. Study design No. of patients
(+ON/−ON)
Underlying
disease
Daily dose Treatment duration Cumulative dose Site of lesion Notes
Marsh et al.
[76]
Retrospective Group A: 21%
Group B: 0%
Aplastic anemia Group A: methylprednisolone
5 mg/kg/day
Group B: methylprednisolone
1 mg/kg/day
2–4 weeks NA Femoral head
most common,
knee, 1 patient
with humeral
head
AVN only seen in high dose group.
Enright et al.
[73]
Retrospective 28/902 Post-BMT Mean dose/day in 1st month: 0.82
mg/kg/day, and was 2.2 mg/kg/day
during the second 30 days after
transplantation (reflecting increased
steroid need for GVHD)
NA The mean cumulative dose of
steroids to onset of avascular
necrosis was 19.8 g/patient
(range 9 to 70.0 g)
The hip joint was
most often involved
(64% of patients),
followed by knee
(61%), ankle (29%),
shoulder (21%), and
elbow (7%).
Significant correlation between the total
cumulative dose of steroids and number of
joints involved (pb0.01). A multivariate
analysis (allogeneic transplant patients
only) identified acute or chronic GVHD
requiring steroid therapy (p=0.003),
and increasing age (p=0.002) as
significant and independent risk factors.
Felson et al.
[21]
Metanalysis
of 22 studies
22 pooled
studies
AVN range 0–31%
(SLE, renal transplant,
BMT, Hodgkin's)
1st month, 3 months, 6 months, and
12months (total steroid/oral steroid),
respectively were 127/80, 74/50,
49/34, 29/25.
1-, 3-, 6-, and
12-month periods
NA NA +Relationship between oral dose in each
time period and development of AVN
Comparing steroid dose and bolus steroids
indicated that a 9000mg prednisone
(equivalent) cumulative dosage given in a
month had a 22% incidence of AVN.
Bolus dose was not associated with AVN.
This quantitative review strongly suggests
that steroid dose is the major predictor of the
risk of AVN.
The oral dose effect amounts to a 4.6%
increase in the risk of AVN for every
10 mg/day rise in oral steroids during the first
6 months of therapy
Draw backs: only a small number of non-
renal cohorts in study (SLE patients shave
different risks!)
Atkinson et al.
[136]
Retrospective 5/50 Aplastic anemia–
post-BMT
NA N14 days Total dose of 14 mg/kg Femoral head Minimization of steroids in prophylaxis of
GVHD to prevent AVN complication
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741C. Powell et al. / Autoimmunity Reviews 9 (2010) 721–743may include underlying disease, increased oxidative stress and high
dose corticosteroids. Furthermore, neurosurgical indications for corti-
costeroids are usually for a short duration (often b24 h) of treatment
with high doses. In the 2 studies included in this table [58,59], both
authors recognize steroids as a risk factor that should be carefully
minimized in duration and dose. However, neither found statistically
significant association with daily or cumulative dose. Felson et al., also
included 1 neurosurgical study out of the 22 others examined.
10.4. Daily and cumulative dosing in SARS and aplastic anemia patients
In a study of SARS patients, Chan et al. [75], concluded that
cumulative doses of N2000 mg of MPSL and duration of therapy
N18 days were statistically significant risk factors for development of
osteonecrosis. Li et al. [135], also concurred that high cumulative dosing
and long duration of therapy conferred the highest risk. With regard to
aplastic anemia,Marsh et al. [76] found that osteonecrosis only occurred
in the high steroid dose group (5 mg/kg/day vs. 1 mg/kg/day of MPSL).
11. Discussion
The risk of corticosteroids on the development of osteonecrosis is
dependent on daily dose, cumulative dose, maximum dose and route
of administration, as well as underlying disease states. In addition,
there are genetic factors that have not yet been identified. Parenteral
or oral steroids are more likely to lead to osteonecrosis. The highest
daily dose, or, to a lesser extent, cumulative dose is directly correlated
with the risk of developing osteonecrosis. Osteonecrosis is rare in
patients who are on very short course, low dose protocols. Topical and
inhaled steroids have been reported to be associated with osteone-
crosis, but these cases were confounded by the use of oral or
parenteral steroids as well. No cases of osteonecrosis were found that
were associated with the use of topical or inhaled steroids alone.
Unfortunately, only the minority of affected cases are ever reported.
Due to the absence of subjective and objective findings in the
initial phases of the disease, early diagnosis of osteonecrosis depends
on the ability of the physician to maintain a high index of suspicion.
Once symptoms have presented, the disease may have already
progressed to phases of irreversible damage. Treatment in these
later stages of the disease is suboptimal and invariably involves
surgical procedures, including total hip replacement.
Currently there are no guidelines that define a safe threshold dose
of steroids. This paper attempts to establish some recommendations
for the administration of steroids. In many cases, the use of steroids is
unavoidable, but knowing the likelihood of developing osteonecrosis
as a complication of steroid use may help in early detection of the
condition.
12. Concluding remarks
The risk of osteonecrosis from corticosteroids remains a significant
cause of morbidity. Physicians should be aware of this risk and
patients should be informed consumers when corticosteroids are
prescribed. Indeed, we suggest the following recommendations:
1. Health care providers should be aware of the potential risk for
osteonecrosis in patients treated with corticosteroids, especially
parenteral or oral preparations, and with certain specific underly-
ing disease states.
2. Patients who receive steroids via other routes, such as IA, inhaled
or intranasal, have a low but not zero risk of developing
osteonecrosis. There is the potential for developing osteonecrosis
when high doses of inhaled corticosteroids are used, such as in
severe persistent asthma or eosinophilic esophagitis.
3. Patients should always be informed of the risk of developing
osteonecrosis whenever steroids are used.A more complete understanding of the pathogenesis of osteone-
crosis may help us establish more precise guidelines in the future.
Until then, the use of a “therapeutic checklist”, such as that proposed
by Weldon et al. [77], may be a useful means of identifying those
patients at particular risk and minimizing, whenever able, the use of
steroids at every decision crossroad.Take-home messages
• Corticosteroids remain a life-saving medication but do carry risk
factors, including potential development of osteonecrosis.
• Patients with autoimmune disease have themselves an increased
risk of osteonecrosis but carry an increased burden secondary to the
use of corticosteroids.
• Physicians should be aware of this complication as earlier diagnosis
may lead to a significantly improved outcome.
• The risk of development of osteonecrosis is both dose and duration
dependent but there are clearly individual differences that explain
different patient susceptibility to development of this complication.References
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